Physician profile
Mark J Jagust
NPI 1467493494
$3,260.67
in general payments reported to CMS, 2019-2025
22 companies · $504 in 2025
The $504 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $287 · 2020: $194 · 2021: $190 · 2022: $665 · 2023: $632 · 2024: $788 · 2025: $504.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,924.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,924.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $683.17 | 2019-2025 | Otezla, Repatha, Evenity |
| Regeneron Healthcare Solutions, INC. | $446.11 | 2023-2025 | Dupixent |
| Abbvie INC. | $411.45 | 2021-2024 | |
| Novo Nordisk INC | $402.00 | 2020-2023 | Wegovy |
| Novartis Pharmaceuticals Corporation | $373.63 | 2022-2025 | |
| Lilly USA, LLC | $302.67 | 2020-2025 | Jardiance, Zepbound, Emgality |
| Pfizer INC. | $87.74 | 2019-2025 | |
| Inspire Medical Systems, INC. | $69.47 | 2024-2025 | Inspire |
| Glaxosmithkline, LLC. | $57.24 | 2021-2022 | |
| Exact Sciences Corporation | $56.60 | 2025 | The Cologuard Plus Collection Kit |
| Astellas Pharma US INC | $50.18 | 2023-2024 | Veozah |
| Astrazeneca Pharmaceuticals LP | $48.63 | 2020-2022 | |
| Arbor Pharmaceuticals, INC. | $46.01 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $42.09 | 2020-2021 | |
| Axsome Therapeutics, INC. | $33.08 | 2025 | Auvelity |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $31.51 | 2023 | Quviviq |
| Daiichi Sankyo INC. | $27.80 | 2023 | Injectafer |
| Amarin Pharma, INC. | $25.51 | 2020-2023 | |
| Abbott Laboratories | $20.53 | 2024 | Freestyle Libre 3 |
| Antares Pharma, INC. | $18.39 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $15.54 | 2022 | |
| Aytu Biopharma, INC. | $11.32 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Jagust listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.